Zogenix inc (NASDAQ:ZGNX) currently has a “Buy” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Buy” signal. 10 – 8 Day Moving Average Hilo Channel shows “Buy” signal. While 20-Day Moving Average VS Current Price shows “Buy” Signal.
Zogenix inc (NASDAQ:ZGNX) gained 20.73 Percent and closed its previous trading session at $55.9. The stock traded with the average Volume of 528.17 Million at the end of last session.
Zogenix inc (NASDAQ:ZGNX) has the Market Capitalization of 1.95 Billion. The Stock has its 52-week High of $58.30 and 52-Week Low of $10.05 and it touched its 52-week high on 07/12/18 and 52-Week Low on 08/11/17
The company reported its last earnings Actual EPS of $-0.87/share. While, the analyst predicted that the company could provide an EPS of $-0.74/share. Hence the difference between Predicted EPS and Actual EPS reported is $-0.13/share which shows an Earnings Surprise of -17.6 Percent.
Sell side analysts plays vital role in buying and selling a stock where 1 analysts rated Zogenix inc (NASDAQ:ZGNX) as Buy, 0 analysts given Outperform signal, 0 reported Hold, and 0 analysts rated the stock as Sell.
The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 23.77% where SMA50 and SMA200 are 31.35% and 41.83% respectively.
The company shows its Return on Assets (ROA) value of -45.9%. The Return on Equity (ROE) value stands at -76%. While it’s Return on Investment (ROI) value is -29.4%.
Zogenix inc (NASDAQ:ZGNX) currently has a Weekly Volatility of 5.22% percent while its Monthly Volatility is at 4.55% percent. While talking about Performance of the Stock, Zogenix inc currently has a Weekly performance of 27.19%, monthly performance percentage is 25.06 percent, Quarterly performance is 39.75 percent, 6 months performance shows a percent value of 60.86% and Yearly Performance is 273.91 percent.
Zogenix, Inc. is a pharmaceutical company engaged in the development and commercialization of treatment products for central nervous system disorders and pain. Its first commercial product, Sumavel, DosePro, is a needle-free Delivery System used in the treatment of acute migraine and cluster headache in a pre-filled, single-use delivery system. Its lead product candidate, ZX002, is a novel, oral and single-entity controlled-release formulation of hydrocodone used for the treatment of moderate to severe chronic pain in patients requiring around-the-clock opioid therapy. Zogenix, Inc. is headquartered in San Diego, CA.